Pelareorep + Letrozole + Atezolizumab + Trastuzumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Mar 29, 2019 → Apr 20, 2022
NCT ID
NCT04102618About Pelareorep + Letrozole + Atezolizumab + Trastuzumab
Pelareorep + Letrozole + Atezolizumab + Trastuzumab is a phase 1 stage product being developed by Biotech Research Group for Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04102618. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04102618 | Phase 1 | Terminated |
Competing Products
20 competing products in Breast Cancer